Induced expression of the Abcb1 drug transporter often occurs in tumors in response to chemotherapy. The role that epigenetic modifications within the ABCB1 promoter play in Abcb1 expression remains unclear. We selected MCF-7 cells for survival in increasing doses of chemotherapy drugs, and assessed the methylation status of 66 CpG sites within the ABCB1 promoter preceding, accompanying and following the onset of drug resistance. Increased ABCB1 transcript expression coincident with acquisition of resistance to epirubicin or paclitaxel was temporally associated with hypomethylation of the ABCB1 downstream promoter in the absence of gene amplifications or changes in mRNA stability. Treatment of control MCF-7 cells with demethylating and/or acetylating agents increased ABCB1 transcript expression. In addition to broad promoter hypomethylation, dramatic reductions in the methylation of specific CpG sites within the promoter were observed, suggesting that these sites may play a predominant role in transcriptional activation through promoter hypomethylation. Furthermore, our data suggest that allele-specific reductions in ABCB1 promoter methylation regulate promoter usage within paclitaxel-resistant cells. This study provides strong evidence that changes in ABCB1 promoter methylation, ABCB1 promoter usage and ABCB1 transcript expression can be temporally and causally correlated with the acquisition of drug resistance in breast tumor cells.
Introduction
Multidrug resistance (MDR) is a major reason for the failure of chemotherapy treatment in breast cancer. Tumors can have either an innate or acquired ability to evade death by multiple structurally unrelated chemotherapeutic agents. 1 Increased expression and drug efflux by ATP-binding cassette (ABC) drug transporters, particularly Abcb1 (Mdr1, P-glycoprotein), have been extensively shown to mediate MDR in vitro. 2, 3 Although the contribution of Abcb1 to MDR is well known, the mechanism by which it becomes upregulated in tumor cells remains unclear.
Epigenetic control is emerging as a prominent mechanism of gene regulation in mammalian cells. Recent studies suggest that changes in ABCB1 expression in certain types of cancers are correlated with epigenetic alterations. In particular, the ABCB1 promoter has been shown to be hypomethylated in several drug-resistant sub-lines of human leukemia (CCRF-CEM and HL60), 4, 5 human epidermoid (KB3-1) 6 and prostate cancer (DU145) cells. 7 Similarly, one study examined differences in methylation between the ABCB1 5 0 -untranslated regions of drug-resistant and drugsensitive breast cancer cells. 8 This study established a correlation between increased ABCB1 expression and hypomethylation of the ABCB1 promoter by comparing the methylation of CpG dinucleotides within the ABCB1 downstream promoters of MCF-7 and MCF-7/ADR cells. 8 Although the evidence presented is compelling, the conclusions are suspect, since the drug-resistant cell line used in this study (MCF-7/ADR) has been shown to be of ovarian origin and is unrelated to MCF-7 breast tumor cells. 9 Another study identified changes in ABCB1 promoter methylation in doxorubicin-resistant MCF-7 cells, compared with parental MCF-7 cells. 10 However, the conclusions of this study were based on assessment of only a few methylation sites. 10 Consequently, a rigorous, comprehensive investigation of the role of ABCB1 promoter methylation in the induction of drug resistance in breast cancer cell lines has yet to be conducted.
Another major issue that remains unaddressed for any tumor cell type is the temporal relationship between changes in promoter DNA methylation and both induction of gene expression and acquisition of drug resistance. Many studies have simply compared drug-sensitive tumor cells with tumor cells selected for resistance to high concentrations of chemotherapy agents. 8, 11, 12 These and other studies have not examined whether changes in the methylation status of CpG dinucleotides (in any gene) are temporally or causally correlated to acquisition of drug resistance. In addition, most epigenetic studies have assessed changes in ABCB1 promoter methylation in response to selection for resistance to a single chemotherapy drug (primarily doxorubicin). Thus it is not clear at present whether selection for resistance to a variety of classes of ABCB1-inducing chemotherapy agents results in changes in ABCB1 promoter methylation.
A novel system to study changes in ABCB1 promoter methylation during acquisition of drug resistance in breast cancer cells has been developed within our laboratory. This system consists of three panels of isogenic MCF-7 cell lines selected for survival in increasing concentrations (doses) of epirubicin, doxorubicin or paclitaxel until maximum resistance is achieved (MCF-7 EPI , MCF-7 DOX-2 and MCF-7 TAX-2 cells, respectively). 13 Cells were also 'selected' in the absence of drug to serve as co-cultured control cells (MCF-7 CC cells). Samples of cells were stored at each drug dose during the selection process, which enabled us to study the precise events preceding, accompanying and following acquisition of drug resistance, including whether epigenetic changes (such as promoter hypomethylation) are correlated with acquisition of drug resistance. Analysis of the cell lines revealed that a specific 'threshold' selection dose (dose-9) had to be reached before any resistance to chemotherapy drugs was observed (31.5 nM epirubicin, 29.1 nM doxorubicin, 3 .66 nM paclitaxel). Furthermore, acquisition of drug resistance involved multiple changes in gene expression, 14 including upregulation of ABCB1 expression in MCF-7 EPI and MCF-7 TAX-2 cells (but not in MCF-7 DOX-2 cells even at the highest selection dose). Elevated ABCB1 transcript expression was first detected at selection dose-9 and progressively increased to selection dose-12 13 . No other drug transporters known to play a role in drug resistance in vitro were expressed in MCF-7 EPI and MCF-7 TAX-2 cells. Inhibition of Abcb1 activity using cyclosporine-A partially restored drug sensitivity in MCF-7 TAX-2 and MCF-7 EPI at selection doses-9 and/or 12, further implicating Abcb1 as a contributor to drug resistance in these cell lines. 13 In this study, we examined the role of epigenetic mechanisms in the induction of both ABCB1 gene expression and drug resistance in MCF-7 EPI and MCF-7 TAX-2 cells. We report that gene amplification and mRNA stabilization do not contribute to increased ABCB1 expression at or above the dose required to achieve drug resistance. In contrast, bisulfite sequencing data indicated that broad hypomethylation of the ABCB1 downstream promoter temporally correlated with acquisition of drug resistance in MCF-7 EPI and MCF-7 TAX-2 cells. Through profiling DNA methylation changes at 66 CpG sites during the acquisition of drug resistance, we were able to determine a common pattern of drug-induced epigenetic changes as well as key sites that have dramatically reduced methylation associated with ABCB1 transcription. Moreover, our data indicate that allele-specific changes in the methylation of the ABCB1 downstream promoter can regulate promoter usage within the ABCB1 gene in drug-resistant MCF-7 cells. Taken together, this study provides compelling evidence that acquisition of drug resistance in breast tumor cells can be temporally and causally related to reductions in the methylation of the ABCB1 downstream promoter.
Materials and methods
Cell culture and drug treatments MCF-7 DOX-2 , MCF-7 EPI and MCF-7 TAX-2 cells were created by selecting MCF-7 cells for survival in increasing concentrations (doses) of doxorubicin, epirubicin or paclitaxel, respectively, until maximum resistance was obtained as previously described. 13 Aliquots of cells were stored at each of the 12 selection doses. Similarly, 12 MCF-7 CC sub-lines were produced by 'selection' in the absence of drug. MCF-7 CC cells were maintained in Dulbecco's modified Eagles' medium supplemented with 10% FBS at 37 1C and 5% CO 2 , while MCF-7 DOX-2 , MCF-7 EPI and MCF-7 TAX-2 cells were maintained in an identical medium supplemented with the chemotherapeutic drugs (at the various doses to maintain selective pressure).
Generation of mammalian cell clones
Individual clonal isolates of MCF-7 CC and MCF-7 TAX-2 cells (selected to dose-12) were prepared by seeding cells at low density in semi-solid media (1.8% methylcellulose (Sargent Welch Laboratories, Buffalo Grove, IL) in 1 Â IMDM media (Princess Margaret Hospital, Toronto, ON) and 30% fetal bovine serum) so as to obtain colonies originating from a single cell. Colony formation was permitted for approximately 10 days, after which single colonies were selected and seeded in 96 well plates containing Dulbecco's modified Eagles' medium. Cells were allowed to adhere to 96-well plates for 4 days, after which MCF-7 TAX-2 cells were transferred to identical medium containing 99 nM paclitaxel (dose-12 concentration). MCF-7 CC cells were maintained and propagated in drug-free media. The cells were propagated sequentially in 96-well plates, 24-well plates, six-well plates and T-25 cm 2 flasks (Sarstedt, Montreal, QC, Canada), with replating when cells reached 60-80% confluence. Seven and nine clonal isolates of MCF-7 CC and MCF-7 TAX-2 cells, respectively, were propagated for further experimentation.
Immunohistochemistry
The expression levels of the Abcb1 protein in MCF-7 CC , MCF-7 EPI and MCF-7 TAX-2 cells were first examined using immunofluorescence confocal microscopy following standard approaches. MCF-7 CC , MCF-7 EPI and MCF-7 TAX-2 cells were selected to dose-12 (852 nM epirubicin or 99.0 nM paclitaxel in the latter two cell lines, respectively) and grown on sterile coverslips in six-well tissue culture plates. Cells were fixed in 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 for 5 min and incubated in blocking buffer (10% horse serum, 1% bovine serum albumin, 0.02% NaN 3 in phosphate-buffered saline) for 1 h at room temperature. A mouse monoclonal Abcb1 antibody (UIC2; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was then added at a 1:10 dilution in standard Tris-buffered saline with 1% bovine serum albumin, followed by addition of a fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody (ID Labs, London, ON, Canada) at a 1:500 dilution in Tris-buffered saline, 1% bovine serum albumin. The coverslips were mounted on glass microscope slides for observation by confocal microscopy (LSM 510 Meta; Carl Zeiss, Toronto, ON, Canada) with a 63 Â objective lens. The laser line used for excitation was Argon 488 nm and the bandpass filter setting used for detection was LP 505. All slides in each experiment were examined on the same day, with triplicate experiments performed.
Flow cytometry
Abcb1 protein expression was further examined by flow cytometry in MCF-7 CC , MCF-7 DOX-2 , MCF-7 EPI and MCF-7 TAX-2 cells (selected to dose-12) using the Abcb1-specific primary antibody MRK16 (Kamiya Biomedical Company, Seattle, WA, USA) as previously described. 15 For each cell line, 2.5 Â 10 5 cells were placed in a 10-cm tissue culture plate and the cells permitted to grow for 48 h. The cells were released from their plates by trypsin/EDTA treatment, washed twice with phosphate-buffered saline and resuspended in 100 ml of phosphate-buffered saline containing 1% bovine serum albumin (PBA). A 5-ml volume of MRK16 antibody was incubated with the cell suspension for 1 h. The cells were washed twice in PBA and resuspended in 60 ml of PBA. A 2-ml volume of fluorescein isothiocyanate-conjugated goat anti-mouse secondary antibody (ID Labs) was added and the cells were incubated in the dark at 4 1C for 30 min. Cells were then washed twice in PBA, resuspended in 100 ml of 1% paraformaldehyde and incubated at room temperature for 10 min. A 400-ml volume of PBA was added. Ten thousand events were examined with the flow cytometer (Cytomics FC 500; Beckman Coulter, Mississauga, ON, Canada) in three independent experiments. Background fluorescence was determined for MCF-7 CC cells using an isotypic control antibody as the primary antibody.
Quantitative PCR with genomic DNA Differences in the copy number of the ABCB1 gene were assessed in quantitative PCR experiments using 0.5 ng of genomic DNA extracted from MCF-7 CC , MCF-7 EPI and MCF-7 TAX-2 cells at selection dose-12, as previously described. 16 A standard curve for ABCB1 was generated using 2, 1, 0.5, 0.25 and 0.125 ng of genomic DNA. The mean quantity of ABCB1 gene was normalized to the S28 gene. Fold changes were then calculated using normalized MCF-7 EPI and MCF-7 TAX-2 values related to the MCF-7 CC cell line.
Fluorescence in situ hybridization
The number of copies of ABCB1 relative to a chromosome-7 centromere probe was investigated in MCF-7 CC , MCF-7 EPI and MCF-7 TAX-2 cells selected to dose-12, as previously described. 16 The gene copy number was determined using a Metasystem-equipped microscope with Metafer4/Metacyte software v3.3.101. A minimum of 105 cells were analyzed for each cell line.
mRNA stability
The stability of ABCB1 mRNA was determined in MCF-7 CC , MCF-7 EPI and MCF-7 TAX-2 cells selected to dose-9 in four independent experiments. Cells grown to 40% confluence were treated with actinomycin-D at the concentration that inhibited incorporation of [5,6 3 H]-UTP at or above 95% (10 mg ml À1 for MCF-7 CC and MCF-7 TAX-2 cells, 100 mg ml
À1
for MCF-7 EPI cells). RNA was extracted at 0, 1, 2, 4, 6 and 24-h post treatment using an RNeasy kit (Qiagen, Mississauga, ON, Canada) as per manufacturer's protocols. Transcript levels were then determined by quantitative reverse transcription PCR (Q-PCR) as previously described.
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Bisulfite sequencing PCR The methylation status of CpG sites within the ABCB1 downstream promoter was determined by bisulfite sequencing PCR (BSP), as previously described, 16 with genomic DNA extracted from MCF-7 CC cells at selection doses 1, 8 and 12. ABCB1 promoter methylation was also examined in MCF-7 DOX2 cells at selection doses 8 and 12, and in both MCF-7 EPI and MCF-7 TAX-2 cells at selection doses 8, 9 and 12. The methylation status of the upstream promoter was not ABCB1 promoter hypomethylation and drug resistance K Reed et al investigated due to the paucity of CpG islands in this region. 16 Sequencing of positive clones was performed by Mobix DNA sequencing service (McMaster University, Hamilton, ON, Canada). Changes in methylation at individual CpG sites were calculated by subtracting the average percentage methylation for the lower dose from the higher dose at each site.
Effects of DNA methylase or histone deacetylase inhibitors on ABCB1 expression in MCF-7 CC cells MCF-7 CC cells ('selected' to dose-12) were seeded at less than 50% confluence and allowed to adhere overnight at 37 1C prior to treatment with 5-aza-2 0 -deoxycytidine (Aza) (Methylation Ltd, Port Orange, FL, USA; 1 mM) for 96 h (alone or in combination with the histone deacetylase inhibitor trichostatin-A (TSA; Sigma Laboratories, Oakville, ON, Canada; 50 ng ml
À1
) for 48 h). Media and/or Aza/TSA replacement occurred every 24 h. DNA demethylation by Aza treatment was confirmed by bisulfite sequencing PCR (using 10 bacterial clones) while acetylation by TSA treatment was confirmed by measuring histone acetylation using a cell-based ELISA kit, as per manufacturer's protocol (CycLex Co Ltd, Nagano, Japan). RNA was extracted from the cells at 96 h, reverse-transcribed into cDNA and Q-PCR experiments performed using cDNA from untreated, Aza-treated and Aza/TSA-treated MCF-7 CC cells and primers specific for ABCB1 or S28, as previously described. 17 A minimum of three independent experiments containing triplicate samples were performed. Genomic DNA was used for bisulfite sequencing as described above. 
Pyrosequencing

ABCB1 expression and promoter usage
To investigate the relative abundance of ABCB1 transcripts derived from the upstream and downstream promoters, Q-PCR experiments were performed using cDNA prepared from RNA isolated from MCF-7 CC , MCF-7 EPI and MCF-7 TAX-2 cells (selected to dose-12) and primers specific for transcripts derived from the upstream promoter or from both promoters as previously described. 16 Duplicate experiments with triplicate samples were performed.
Analysis of ABCB1 expression and ABCB1 upstream promoter usage within 12 clonal isolates of MCF-7 CC and MCF-7 TAX-2 cells (selected to dose-12) was conducted as previously described. 16 Mean quantities were determined for triplicate wells and normalized to S28 expression. Fold changes within 12 clones of MCF-7 CC and MCF-7 TAX-2 cells were calculated relative to the normalized mean quantity of their respective populations.
Statistical analysis
A Gaussian distribution was tested using the D'Agostino and Pearson omnibus normality test to determine the use of parametric or non-parametric statistical tests. Significance was then tested with Mann-Whitney non-parametric twotailed t-tests (a ¼ 0.05). The significance of percentage methylation between MCF-7 CC and MCF-7 TAX-2 biological clones and their respective populations was tested relative to their populations by one-way analysis of variance (a ¼ 0.05) and Tukey's post hoc analysis. Pearson correlation coefficients (r) were calculated for ABCB1 gene expression and ABCB1 promoter methylation.
Results
Increased Abcb1 protein levels upon acquisition of drug resistance in MCF-7 EPI and MCF-7 TAX-2 cells Examination of Abcb1 protein expression by flow cytometry and immunofluorescence microscopy confirmed our previous findings that MCF-7 CC and MCF-7 DOX-2 cells selected to dose-12 did not express appreciable amounts of Abcb1 protein (Figures 1a and b) . In contrast, MCF-7 EPI and MCF-7 TAX-2 cells at selection dose-12 expressed the Abcb1 protein predominantly at the cell membrane ( Figure 1b Decreased methylation of the ABCB1 downstream promoter temporally correlated with increased ABCB1 expression and the acquisition of drug resistance Bisulfite sequencing data indicated that relative to MCF-7 CC and MCF-7 DOX-2 cells, the ABCB1 downstream promoters in MCF-7 EPI and MCF-7 TAX-2 cells were significantly hypomethylated upon acquisition of drug resistance (dose-9) and at the highest selection dose (dose-12). This conclusion was based on an assessment of the total and average percentage ABCB1 promoter methylation across the cell lines at selection doses 8, 9 and 12 ( Figure 3a) . Similar conclusions were drawn by examining the average methylation of specific CpG sites in the ABCB1 promoter of the various cell lines at selection doses 8, 9 and 12 (Figures 3d-f) . The methylation data for each bacterial clone used to determine the minimum mean percent ABCB1 promoter methylation for MCF-7 CC cells, MCF-7 EPI cells at selection doses 8, 9 and 12, and MCF-7 TAX-2 cells at selection doses 8, 9 and 12, are shown in Figure 4 . Pyrosequencing analysis confirmed significant hypomethylation of MCF-7 TAX-2 cells relative to MCF-7 CC cells at selection dose-12 (Table 1) (Figures 3a and b) . The average percentage methylation for the 59 clones from MCF-7 CC cells was 70.1% across the selection doses (Figure 3a) .
Interestingly, when two populations (a hypermethylated population (X50% of CpG sites methylated) and a hypomethylated population (o50% of CpG sites methylated)) were defined, differences in ABCB1 downstream promoter methylation between MCF-7 CC cells and MCF-7 EPI or MCF-7 TAX-2 cells were enhanced for the hypomethylated population ( Figure 3c and data not shown). Both hypermethylated and hypomethylated populations occurred in similar proportions in drug-resistant MCF-7 EPI and MCF-7 TAX-2 cells when the classifier of 50% methylation was used ( Figure 4) . Two prominent populations were not seen in MCF-7 CC cells, at any selection dose, as only 8 of the 59 clones had ABCB1 downstream promoters that were methylated below 50% (Figure 4a ). The average percentage methylation of the eight hypomethylated MCF-7 CC bacterial clones was 43.1%. The lowest level of ABCB1 promoter methylation in MCF-7 CC cells was 39.4%. In contrast, the mean percentage methylation of the ABCB1 downstream promoter in MCF-7 EPI cells at selection doses 9 and 12 was 15.5 and 21.4%, respectively. The minimum level of methylation was 0 and 1.5%, respectively, and the median percentage methylation was 1.5 and 18.2%, respectively. Similarly, average percentage methylation of the ABCB1 downstream promoter in MCF-7 TAX-2 cells at selection doses 9 and 12 was 34.8 and 3.0%, respectively, while minimum average percentage methylation was 33.3 and 0%, respectively. Correlations between ABCB1 gene expression and promoter methylation Pearson correlation coefficients (r) were calculated for the relationship between ABCB1 gene expression and ABCB1 downstream promoter methylation in the MCF-7 TAX-2 and MCF-7 EPI cell lines at various selection doses. MCF-7 TAX-2 cells selected to doses 8, 9 and 12 had a Pearson correlation coefficient for these two parameters of À0.97 (Table 2) . MCF-7 EPI cells selected to doses 8, 9 and 12 had a Pearson correlation coefficient of À0.27 (Table 2) , likely due to the considerably higher ABCB1 mRNA expression at dose-12 (compared with dose-9), but similar reductions in the level of ABCB1 promoter methylation at these two doses. A strong negative correlation between ABCB1 gene expression and ABCB1 promoter methylation for MCF-7 EPI cells was obtained when the analysis was restricted to selection doses 8 and 9, suggesting a particular importance of promoter hypomethylation in the onset of ABCB1 gene expression and drug resistance in these cells. (Figure 3a) , which approached significance (P ¼ 0.064). Similar to the drug-resistant cell lines, both highly and lowly methylated populations were observed in equivalent proportions by BSP analysis of bacterial clones housing bisulfite-treated, PCR-amplified DNA from Aza-treated MCF-7 CC cells (Figure 3b Most changes in the methylation of ABCB1 CpG sites that occurred between doses 1 and 12 in MCF-7 CC cells were small increases in methylation (Figure 5e ). In contrast, mainly large reductions in methylation were observed across several CpG sites when MCF-7 CC cells were treated with Aza (Figure 5f ), or when MCF-7 cells acquired resistance to epirubicin (Figure 5g ) or to paclitaxel (Figure 5h ). Only CpG sites 13 and 47 within the ABCB1 promoter of MCF-7 EPI cells and site 45 within MCF-7 TAX-2 cells increased methylation (Figures 5g and h, respectively) . Small increases in methylation in response to Aza treatment occurred at CpG sites 3, 22, 49-51, 54 and 57 of the MCF-7 CC promoter (Figure 5f ). CpG sites that exhibited the most striking reductions in methylation within MCF-7 EPI Table 4 (along with the corresponding CpG sites contained within the regions).
In addition to distinct changes in methylation induced by selection with paclitaxel or epirubicin, common reductions in methylation took place upon selection for epirubicin or paclitaxel resistance. For example, most sites within the 3 0 -end of the promoter (CpG sites 49-66) exhibited dramatic reductions in methylation, while this region was largely unchanged upon Aza treatment of MCF-7 CC cells. This region containing CpG sites 49-66 includes the translation start site (Table 3 ) and an element important for negative ABCB1 promoter hypomethylation and drug resistance K Reed et al regulation by p53 (Table 4 ). Other regional reductions in methylation that were similar upon selection for drug resistance and upon Aza treatment occurred around sites 19-22, which correspond to the consensus Inr site and the transcription start site (Table 3) , and sites 32-44, involved in regulation by p53 (Table 4) . CpG Site 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 CpG Site 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60 62 64 66 CpG Site 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 ) by Q-PCR experiments using primers that detect transcripts from the upstream promoter ('upstream' primers) or from both upstream and downstream promoters ('total' primers). MCF-7 CC cells expressed very low amount of ABCB1 transcript, which appeared to be derived solely from the upstream promoter (since the level of total transcripts and the level of transcripts from the upstream promoter were identical; Figure 7a ). In contrast, the amplification plots for both MCF-7 EPI and MCF-7 TAX-2 cells revealed significantly higher ABCB1 expression in these cells, with transcripts emanating from both upstream and downstream ABCB1 promoters (Figures 7b and c, respectively) .
Quantification of transcripts from upstream and downstream
Methylation levels and promoter usage in clonal isolates of MCF-7 CC and MCF-7 TAX-2 cells were comparable to that of the population Two populations with dissimilarly methylated ABCB1 downstream promoters were evident by BSP analysis of bacterial clones housing DNA from MCF-7 TAX-2 cells. ABCB1 transcription via both upstream and downstream ABCB1 promoter was also evident. This raised the possibility that two MCF-7 TAX-2 cell populations exist (one with a methylated downstream promoter and usage of the upstream promoter and a second with a hypomethylated active downstream promoter). To assess this possibility, we isolated single clones from MCF-7 CC and MCF-7 TAX-2 cells and examined both their expression of ABCB1 and methylation of their ABCB1 promoters. No significant differences in promoter methylation were observed in clones of MCF-7 CC and MCF-7 TAX-2 cells relative to the entire cell population (Table 1) . Furthermore, all MCF-7 TAX-2 biological clones did express ABCB1 mRNA at levels akin to that of the population, with the greatest difference being 2.22-fold. All MCF-7 TAX-2 clones also used both promoters at comparable levels to the population, with the greatest difference being a 2.45 difference in upstream promoter usage (Table  1) . MCF-7 CC clones also behaved similarly to the population, with both consistent exhibition of low ABCB1 expression and usage of the upstream promoter (Table 1) .
Discussion
Changes in the expression of the ABCB1 drug transporter often occur in tumors and cultured tumor cells upon acquisition of resistance to chemotherapy agents. The exact mechanism responsible for increased ABCB1 expression in drug-resistant cancer cells remains unclear. This study used a unique panel of progressively drug-resistant breast tumor cells to assess the temporal and causal relationships between exposure to specific chemotherapeutics, changes in ABCB1 promoter methylation and acquisition of drug resistance. We have previously shown that a specific threshold drug dose must be reached in order to acquire drug resistance and that multiple molecular mechanisms appear to be associated with the acquisition of drug resistance, including decreased drug accumulation through overexpression of the Abcb1 drug transporter in MCF-7 EPI and MCF-7 TAX-2 cells 13, 14 (unpublished observations). We first examined the possibilities that differences in ABCB1 gene amplification, ABCB1 transcript stability or ABCB1 mRNA translation may account for the higher Heat-shock-like element À99 to À66 None 34 a Adjacent CpG site near to the element.
ABCB1 promoter hypomethylation and drug resistance K Reed et al ABCB1 transcript and Abcb1 protein levels in MCF-7 EPI and MCF-7 TAX-2 cells (relative to MCF-7 CC cells). Previously, we demonstrated that ABCB1 transcript expression was dramatically increased in MCF-7 EPI and MCF-7 TAX-2 cells at threshold dose-9 as compared with MCF-7 CC cells. Expression of ABCB1 increased with increasing selection dose. No increase in ABCB1 expression was observed in these cells at selection doses 1-8 (prior to acquisition of drug resistance). 13 Higher expression of Abcb1 protein levels in MCF-7 TAX-2 cells (and particularly in MCF-7 EPI cells) was confirmed at selection dose-12 by immunoprecipitation and immunoblotting experiments 13 and in this study by flow cytometry and immunofluorescence microscopy ( Figure 1) . The degree of Abcb1 protein expression was consistent with that previously observed at the mRNA transcript level (MCF-7 EPI 4MCF-7 TAX-2 bMCF-7 CC ). 13 This was an important observation as increased expression of ABCB1 at the transcript level is not always accompanied by elevated ABCB1 promoter hypomethylation and drug resistance K Reed et al protein levels. Despite overexpression of ABCB1 mRNA, two independent studies identified a block in the translation of ABCB1 mRNA within K562 cells. 18, 19 Although the possibility exists within our MCF-7 cell lines that all transcripts produced are not translated into protein, the high Abcb1 protein expression levels within MCF-7 EPI and MCF-7 TAX-2 indicates that a translational blockade was not present in these drug-resistant cell lines.
Gene amplification is also a potential mechanism for increased ABCB1 transcription, given previously published findings using a variety of drug-resistant cancer cell lines. [20] [21] [22] [23] No ABCB1 gene amplification could be detected in MCF-7 EPI and MCF-7 TAX-2 cells (relative to MCF-7 CC cells) when assessed by Q-PCR experiments using genomic DNA and ABCB1-specific primers (Figure 2 ). This lack of ABCB1 amplification was further confirmed by FISH studies (Figure 2 ). Interestingly, we have identified gene amplification as a primary mechanism of ABCB1 induction in MCF-7 cells that we selected for resistance to docetaxel (MCF-7 TXT cells). 16 Since gene amplification was not found to contribute to elevated ABCB1 expression in MCF-7 EPI and MCF-7 TAX-2 cells selected in an identical manner, each selection and/or chemotherapy drug used during selection may result in a different mechanism of ABCB1 upregulation. Furthermore, it appears that the same class of chemotherapeutic agents (for example, the taxanes) need not induce ABCB1 expression by the same mechanism(s).
Another possible mechanism for elevated ABCB1 expression within drug-resistant cancer cells is ABCB1 mRNA stabilization. To evaluate the role of this mechanism, the half-life of ABCB1 transcripts was determined through RNA decay experiments using actinomycin-D to prevent synthesis of new transcripts. Since actinomycin-D is a substrate for the Abcb1 drug transporter, 24 the concentration necessary to inhibit 95% of RNA synthesis was determined for each cell line individually prior to use in RNA decay experiments. The stability of the ABCB1 mRNA was not increased within MCF-7 EPI or MCF-7 TAX-2 cells upon the acquisition of drug resistance (selection dose-9; Figures 2g and h) . Consequently, alterations in the stability of ABCB1 transcripts could not account for the higher levels of ABCB1 mRNA and protein found in drug-resistant MCF-7 EPI and MCF-7 TAX-2 cells relative to MCF-7 CC cells.
Due to recent reports of decreased methylation of the downstream ABCB1 promoter in association with drug resistance, [4] [5] [6] [7] 10, 25 we next investigated this mechanism as the possible cause of increased ABCB1 expression in our drug-resistant cell lines. Most of the variation in the degree of promoter methylation within drug-sensitive cell lines (including MCF-7 DOX-2 , MCF-7 EPI and MCF-7 TAX-2 cells selected to dose-8 and MCF-7 CC cells 'selected' to dose-12) occurred within the first 30 CpG sites (Figures 3d and 5a) , which is consistent with the bisulfite sequencing data for MCF-7 cells reported by David et al. 8 Significantly decreased methylation of the ABCB1 downstream promoter was observed in MCF-7 EPI cells at the onset of drug resistance (selection dose-9) both in terms of average promoter methylation (Figure 3a) and methylation across specific CpG sites (Figures 3e and 5c ). Broad promoter demethylation of these sites was maintained at the highest selection dose (dose-12; Figure 5c ). Similar to our observations in MCF-7 EPI cells, CpG sites within the ABCB1 downstream promoter of MCF-7 TAX-2 cells selected to dose-8 were mostly methylated in the clones selected for analysis (Figures 3d  and 5d ). However, ABCB1 promoter methylation was significantly decreased in MCF-7 TAX-2 cells at selection dose-9 and further decreased at selection dose-12 both in terms of average promoter methylation (Figure 3a) and methylation across specific CpG sites (Figures 3e and f, and  5d) . Demethylation of the ABCB1 promoter in MCF-7 EPI and MCF-7 TAX-2 cells as cells were selected from dose-8 to dose-12, was confirmed by pyrosequencing experiments (Table 1) . 26 Further proof of a causal relationship between the epigenetic modifications of the ABCB1 downstream promoter and ABCB1 gene expression was provided in this study through experiments involving application of DNA methyltransferase or histone deacetylase inhibitors (Aza and TSA, respectively). Reduced DNA methylation induced by Aza treatment of MCF-7 CC cells selected to dose-12 (Figures 3a-c and 5b and f) resulted in a moderate induction (seven-fold) of ABCB1 expression, while addition of both Aza and TSA increased ABCB1 mRNA levels by B32-fold (Figure 3g ). This synergy between DNA methyltransferase inhibitors and histone deacetylase inhibitors in stimulating ABCB1 mRNA expression is supported by another study, which showed that TSA or Aza treatment alone had little effect or weakly induced ABCB1 expression, respectively, in CEM-CCRF cells. 27 In contrast, treatment of these cells with both Aza and TSA induced a 10-fold higher level of ABCB1 expression than with Aza treatment alone. The study further showed that Aza-induced demethylation of the ABCB1 promoter resulted in the release of methyl-CpG-binding protein-2 from the promoter, promoter acetylation and partial transcriptional activation at the downstream ABCB1 promoter. 27 Interestingly, another study showed that acetylation of the ABCB1 downstream promoter was dependent upon its methylation state. Partial hypomethylation of the ABCB1 promoter in CEM-Bcl2 cells induced ABCB1 transcription and daunorubicin-induced H3 acetylation of the ABCB1 promoter preceded such changes in ABCB1 expression. 12 The effect of Aza treatment, TSA treatment and combined Aza and TSA treatment on epirubicin or paclitaxel sensitivity was assessed using clonogenic assays. Under identical conditions as those, which induced demethylation of the ABCB1 promoter and increased ABCB1 expression in MCF-7 CC cells, addition of 1 mM Aza to cultures for 96 h consistently prevented colony formation in semi-solid medium, even after 14 days post administration. Similarly, no colony formation was observed when a combination of Aza and TSA was administered to cells. Unfortunately, this prevented us from assessing whether reduced ABCB1 promoter methylation (with and without histone acetylation) was sufficient to induce resistance to epirubicin or to paclitaxel. Thus, while the two agents could induce significant ABCB1 transcript expression, this may or may not have been sufficient to induce drug resistance. The lack of colony formation is likely related to the cytotoxicity of Aza and/or the nonspecific nature of this demethylating agent, which may have affected a variety of cellular processes, including cell adhesion or cell proliferation. Consistent with these hypotheses, dramatic reductions in long-term survival were observed in a clonogenic assay when HeLa cells were treated with 1 mM Aza for 48 h. 28 Aza treatment of these cells also resulted in strong growth inhibition due to arrest of the cell cycle in G 2 . Cell viability was retained at Aza concentrations at or below 100 nM, 28 but this would be expected to result in considerably reduced ABCB1 promoter hypomethylation and Abcb1 expression, making induction of drug resistance less likely.
The effect of TSA treatment alone on epirubicin or paclitaxel sensitivity in MCF-7 CC cells (at the concentration we used above to measure its effects on ABCB1 gene expression) was also assessed using clonogenic assays. TSA treatment of MCF-7 CC cells had no effect on paclitaxel sensitivity. It did, however, increase sensitivity to epirubicin. Since TSA treatment alone had no effect on ABCB1 expression in our study, this enhanced sensitivity could not be attributed to changes in Abcb1 expression or function. Likely, TSA had effects on the acetylation and expression of other genes that affect cellular sensitivity to epirubicin.
In addition to broad changes in methylation, dramatic reductions in the methylation of specific CpG sites were observed in MCF-7 EPI and MCF-7 TAX-2 cells upon acquisition of drug resistance (Figures 5g and h, respectively) . In contrast, increased methylation at various CpG sites were observed upon 'selection' of MCF-7 cells in the absence of drug (Figure 5e ), suggesting that the reductions in ABCB1 downstream promoter methylation were due to selection for drug resistance and not propagation in long-term culture. When comparing drug-sensitive (dose-8) and drug-resistant (dose-12) MCF-7 EPI and MCF-7 TAX-2 cells, similar wave-like patterns of methylation changes were observed across CpG sites. There were particular 'valleys' of reduced CpG site methylation, followed or preceded by areas with little change. A region with strong hypomethylation induced by selection for drug resistance spans CpG sites 49-66. Shared valleys of hypomethylation in drug-resistant and Azatreated cells span CpG sites [19] [20] [21] [22] , which correspond to the consensus Inr site, a site adjacent to the transcription start site (Table 3) , and CpG sites 32-44 implicated in the regulation of ABCB1 expression by p53 (Table 4) . Aza treatment did not result in dramatic reduction in the methylation of CpG sites 49-66 (Figure 5f ). Since the region spanning these sites includes the translation start site (Table  3) and an important element for transcriptional activation by p53 (Table 4) , this may account for the lower levels of ABCB1 expression in Aza-treated MCF-7 CC cells as compared with that in MCF-7 TAX-2 and MCF-7 EPI cells.
It is interesting to note that the first 30 CpG sites within the ABCB1 downstream promoter are more widely distributed than the remaining 36 CpG sites, which are considerably closer in proximity. 8 Such significant reduction in the methylation of a series of closely spaced CpG sites near the site of transcript initiation may induce strong changes in chromatin structure, enabling binding of transcription factors, RNA polymerase-II and other proteins involved in ABCB1 transcription initiation. These regional differences in DNA methylation status may suggest that every CpG site is not equal in importance, but instead there may be critical areas involved in regulating ABCB1 gene expression by DNA methylation.
Dramatic methylation changes distinct to each drugresistant cell line were also observed (Figures 5g and h) . The CpG sites strikingly hypomethylated in MCF-7 EPI cells included sites 1, 4, 30 and 66. Both site-1 and site-4 are within the binding region of T-cell factor (TEF)/lymphoid enhancer factor (LEF) ( Table 4) . Interestingly methylation at site-13 was substantially increased and is located near the binding site of many transcription factors, is also located within the site implicated in regulation by p53, which acts to repress transcription (Table 4) . Thus increased methylation at this site could block repression by p53 thereby inducing transcription. Substantial methylation changes were observed in sites 10-13 within MCF-7 EPI cells, which correspond to CpG sites that may be important in ABCB1 downstream promoter regulation by multiple factors (Table 4) . None of these sites exhibited large changes in methylation in MCF-7 CC cells upon Aza treatment. The greatest methylation changes within the ABCB1 downstream promoter of MCF-7 TAX-2 cells occurred at CpG sites 6-8, 21, 32, 49 and 65, some of which also exhibited striking changes upon Aza treatment of MCF-7 CC cells. The translation start site is located very close to site-64, while site-8 is adjacent to the region regulated by heat-shock factor-1 (HSF-1) (Table 4) , suggesting it may be involved in the regulation of ABCB1 transcription within paclitaxel-resistant cells. It is possible that the dramatic reductions in methylation of CpG sites unique to MCF-7 EPI cells play a particular role in ABCB1 induction, since MCF-7 EPI cells have considerably higher ABCB1 expression than MCF-7 TAX or Aza-treated MCF-7 CC cells.
Interestingly, two populations of differentially methylated ABCB1 promoters were identified in bacterial clones housing bisulfite-treated, PCR-amplified DNA from MCF-7 TAX-2 or MCF-7 EPI cells at selection doses 9 and higher (Figures 3  and 4) . Although this could be indicative of two different members of the cell population (high and very low ABCB1 expressors), this is not supported by examination of Abcb1 protein levels by confocal microscopy and flow cytometry (Figure 1 ). Since Q-PCR experiments demonstrated that both upstream and downstream ABCB1 promoters are active in MCF-7 EPI and MCF-7 TAX-2 cells with heterogeneously methylated ABCB1 promoters (as opposed to the homogenously methylated promoters of MCF-7 CC cells possessing very low ABCB1 expression via the upstream promoter; Figure 7) , it is likely that the entire population of MCF-7 TAX-2 and MCF-7 EPI cells express ABCB1. Therefore, the ABCB1 downstream promoter may exhibit allelic differences in methylation within a given drug-resistant cell. Hypomethylation of the downstream promoter could induce its availability in alleles with this modification, while alleles that maintain methylated downstream promoters may have adapted to activate transcription from the upstream promoter. To address this possibility, the methylation levels of the ABCB1 downstream promoter and the usage of the ABCB1 upstream promoter were investigated in clonal isolates of MCF-7 CC and MCF-7 TAX-2 cells (selected to dose 12). No significant differences in ABCB1 promoter methylation were observed amongst clonal isolates of MCF-7 CC or MCF-7 TAX-2 cells (Table 1 ). All MCF-7 TAX-2 and MCF-7 CC clones expressed the ABCB1 transcript and used the upstream and downstream promoters at comparable levels to the population (Table 1) . Similar findings would be expected for the clonal isolates derived from drug-resistant MCF-7 EPI sub-lines that displayed hypoand hypermethylated populations. Interestingly, Aza-induced demethylation of MCF-7 CC cells also produced hypoand hypermethylated ABCB1 downstream promoters as determined by bisulfite sequencing analysis of bacterial clones housing DNA from Aza-treated cells. This suggested that some alleles are resistant to Aza-or drug-induced promoter hypomethylation (Figures 3b and c) . Taken together, our findings suggest that the heterogeneously methylated ABCB1 downstream promoters within drugresistant cells by BSP analysis is due to differentially methylated promoters in ABCB1 alleles (and thus differential promoter usage) that occur in the same cells. This result is also supported by our recently published findings indicating that hypermethylation of the downstream ABCB1 downstream promoter upon acquisition of docetaxel resistance in MCF-7 cells results in exclusive usage of the upstream promoter for ABCB1 transcription. 16 There have also been previous reports of allele-specific gene expression linked to allele-specific methylation of genes, 29 although this has not been reported for the ABCB1 gene. However, one study has determined that ABCB1 expression can occur from one allele while the other is transcriptionally silent in drug-resistant cell lines and relapsed lymphoma samples, 30 further supporting differential regulation of ABCB1 alleles.
Currently, very little work has been conducted on epigenetic alterations associated with the acquisition of drug resistance in breast cancer cells. This study provides for the first time strong evidence for a temporal and causal relationship between hypomethylation of a broad number of CpG sites within the ABCB1 promoter, increased ABCB1 expression through changes in promoter utilization and induction of resistance to both paclitaxel and epirubicin in breast tumor cells. This study has thus shown that exposure to different classes of chemotherapeutics can result in hypomethylation of a large number of specific CpG sites with the ABCB1 promoter and that these changes in methylation occur at the onset of drug resistance. This observation emphasized the importance of epigenetics in the acquisition of drug resistance. Changes in DNA methylation of other genes may also be coincident with the acquisition of drug resistance. In addition, our work is the first to demonstrate that differentially methylated promoters in ABCB1 alleles can result in differential promoter usage and raises the possibility that DNA methylation can regulate allele-specific promoter usage in a variety of genes. Aberrant DNA methylation patterns are being investigated as molecular markers to customize individual chemotherapeutic treatments in breast cancers, 31 and this knowledge of ABCB1 methylation changes in association with drug resistance may help to improve our ability to distinguish between drug-sensitive and drug-resistant tumors.
